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Abstract
Background: Brain metastasis (BM) is a poor prognostic factor for non-small-cell lung cancer (NSCLC). The efficacy
and roles of combining temozolomide (TMZ) with whole brain radiotherapy (WBRT) in protection neurocognitive
function (NCF) and improvement quality of life (QOL) were investigated and compared with WBRT alone in the
treatment of NSCLC patients with BM.
Methods: A total of 238 NSCLC patients with BM were reviewed and categorized into WBRT plus TMZ (RCT) arm and
WBRT alone (RT), respectively. The efficacy was evaluated with Pearson chi-square or Fisher’s exact tests, Log-rank test
and Cox proportional hazards model. NCF was assessed by using revised Hopkins Verbal Learning Test (HVLT-R),
Controlled Oral Word Association (COWA) test and Trail-making Test (TMT). QOL was assessed by the Functional
Assessment of Cancer Treatment-Lung (FACT-L) Chinese version 4.0 questionnaire.
Results: The average intracranial objective response (ORR) and disease control rate (DCR) for all the patients were 26.9
and 95.8%, respectively. The intracranial ORR and DCR for RCT and RT arm were 34.9% vs. 20.2% (p = 0.01) and 98.4% vs.
92.7% (p = 0.03), respectively. The median intracranial progression-free survival (PFS) and overall survival (OS) of NSCLC
patients with BM were 5.2 and 7.3 months, respectively. The median PFS of RCT arm was significantly longer than that
of RT arm (5.9 vs. 4.9 months, p = 0.002). The median OS of the RCT arm was also slightly longer than that of the RT
arm (8.5 vs. 5.9 months), but without statistical significance (p = 0.11). Multivariate analysis indicated that TMZ was a
significant factor for PFS. Statistically significant differences on NCF and QOL were observed between CRT and RT arms
at 5 months. RCT showed a trend of toxicities increase compared with RT, however, the toxicities were tolerable and
manageable.
(Continued on next page)
* Correspondence: jinxc1979@hotmail.com; wzxiecongying@163.com
†Equal contributors
2Department of Radiotherapy and Chemotherapy, the First Affiliated Hospital
of Wenzhou Medical University, No.2 Fuxue Lane, Wenzhou 325000, China
1Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder
Research, Wenzhou 325000, China
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Deng et al. BMC Cancer  (2017) 17:42 
DOI 10.1186/s12885-016-3017-3
(Continued from previous page)
Conclusions: Adding TMZ to WBRT in the treatment of NSCLC patients with BM could improve the intracranial ORR,
DCR, and median PFS compared with WBRT alone. Although no remarkable difference on median OS was found, adding
TMZ could prevent NCF and QOL from worsening. The side effects increased by adding TMZ, but the difference was not
statistical significance and toxicities were well tolerated.
Keywords: Temozolomide, Non-small-cell lung cancer, Brain metastases, Whole brain radiotherapy, Neurocognitive
function, Quality of life
Background
Lung cancer has become the leading cause of cancer re-
lated deaths in worldwide [1]. Brain metastasis (BM) is
one of the most common complications in non-small-
cell lung cancer (NSCLC) patients with more than 10%
patients presented with BM at their first hospital visit
[2, 3] and 30–40% patients developed it during the course
of disease [4]. Whole brain radiotherapy (WBRT) is the
standard treatment strategy for BM. However, the progno-
sis of patients with BM remains poor after WBRT with a
median overall survival (OS) of 4–6 months. The effect of
systemic chemotherapy is limited due to the impenetrabil-
ity of brain blood barrier [5, 6], as reported that several
chemotherapy drugs in combination with WBRT failed to
improve the survival [7].
For the past few decades researchers have found that
some drugs may have a positive effect on the NSCLC
with BM [8–10]. Temozolomide (TMZ) is a new oral alkyl-
ating agent, which is able to cross the brain blood barrier
with demonstrated survival benefit in the treatment of
high-grade gliomas when administered concurrently with
adjuvant radiotherapy [11]. Studies demonstrated that
TMZ could be used against a broad range of cancers in
vitro including NSCLC [12–14]. Adding TMZ to WBRT
may improve the response rate of NSCLC patients with
BM [15–17]. However, the potential neurocognitive risks
and the influence on the patients’ living quality of combing
TMZ with WBRT were less studied. The purpose of this
study is to investigate the survival benefits, neurocognitive
function (NCF) and quality of life (QOL) influence of




We retrospectively reviewed NSCLC patients with BM
treated at the First Affiliated Hospital of Wenzhou Med-
ical University from January 2008 to December 2015.
The eligibility criteria for this study were as follows: pa-
tients were historically diagnosed with NSCLC and had
confirmed BM by magnetic resonance imaging (MRI);
had at least one measurable BM with diameter larger
than 10 mm; patients had no history of TKI administra-
tion; had adequate function of major organs (including
cardiac, hepatic, and renal function) and hematologic
function (absolute neutrophil ≥ 1.5 × 109/L or platelet
count ≥100 × 109/L); had no uncontrolled morbidities
(e.g., myocardial infarction in the last 12 months);
with Eastern Cooperative Oncology Group perform-
ance status ≤3; Treated by WBRT with a prescription
of 3 Gy/fraction × 10 fractions.
The exclusion criteria were as follows: patients had
small cell or mixed small cell histology; patients had
EGFR mutations; without at least one measurable lesion
according to the Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1; lost to follow-up or died within
1 month after starting the treatment; received prior radio-
therapy to the brain or TMZ or targeted drugs. This study
was carried out according to ethical standards, national
and international guidelines. It was approved by the
Institutional Review Board and performed at the 1st
Affiliated Hospital of Wenzhou Medical University
(IRB#:2015041). Written informed consent was ob-
tained from each patient before treatment.
Treatment schemes
Patients were divided into WBRT+TMZ (RCT) arm and
WBRT (RT) arm, respectively. WBRT was planned with
two lateral parallel-opposite conformal beams at a prescrip-
tion of 30 Gy for 10 fractions with a 6-MV photon beam
on an Elekta Synergy® linac (Elekta Ltd, Crawley, UK).
WBRT plans were delivered through a record and verify
system (MosaiQ® v. 1.60Q3, IMPAC Medical Systems, Inc.,
Sunnyvale, CA). In the RCT arm, TMZ 75 mg/m2/day was
administered daily during radiation treatment. After the
completion of WBRT, TMZ 100 mg/m2 was continued for
14 days and repeated every 28 days until unacceptable tox-
icity or disease progression for up to six cycles.
Neurocognitive function and quality of life assessment
NCF was assessed by using revised Hopkins Verbal
Learning Test (HVLT-R), Controlled Oral Word Associ-
ation (COWA) test and Trail-making Test (TMT). The
HVLT-R is a learning and memory test, in which the pa-
tient was asked to learn and recall a list of 12 words over
three trials [18]. The TMT is a measure of graphomotor
speed and set-shifting to measure the executive function
[19]. The COWA Test provides a relatively quick test of
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verbal fluency and it is believed to place high demands
on executive control processes [20].
QOL was assessed by the Functional Assessment of
Cancer Treatment-Lung (FACT-L) Chinese version 4.0
questionnaire, which has 34 items with a 5-point Likert
scale [21]. The FACT-L had been shown to be reliable
and valid instruments to measure the QOL of Chinese
lung cancer patients [22].
Treatment evaluation and follow-up
The response and progression were evaluated weekly
during WBRT. Evaluation included a complete history,
neurologic examination, QOL assessment, blood counts,
and biochemistry profile. After RT, the evaluation was
done monthly for the first 6 month, then every 3 months
after. Evaluation included physical examination, neuro-
logic examination, QOL assessment, a complete blood
count measurement, liver function test, and chest
computed tomography (CT) scan. Brain CT with and
without contrast, abdominal CT, or bone scan, as well as
MRI if necessary, were performed when there were
relevant symptoms in patients.
Definitions and statistical analyses
Pearson chi-square or Fisher’s exact tests (when there
were fewer than 5 expected counts in the contingency
table) were used to compare the baseline characteristics
between RCT and RT arms. Tumor response was assessed
according to the Response Evaluation Criteria in Solid
Tumors 1.1. OS was defined as the interval from the date
of initiation WBRT to the date of death resulted from
NSCLC. Intracranial progression-free survival (PFS) was
defined as local disease progression, the appearance of new
intracranial lesions or both. Intracranial PFS was calculated
from the initiation WBRT and the date of confirming pro-
gression or death from intracranial progression (if death oc-
curred within 60 days of the last central nervous system
assessment date). If the complete survival time of a patient
was impossible to obtain or the disease did not progress,
patient’ status was assumed as the last known survival and/
or contact date. The baseline neurocognitive status was re-
corded at the first neurocognitive assessment before the
start of BM treatment. Adverse events were graded accord-
ing to the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) v3.0.
Intracranial PFS and OS were estimated by Kaplan-
Meier method. Differences between groups were com-
pared by the log-rank test. In order to identify risk factors
associated with intracranial progression, multivariate
analyses were conducted with Cox proportional hazard
model. Reliable Change Index was used to categorize the
change or improvement on NCF and QOL scores [23].
The Reliable Change Index was derived from the standard
error of measurement (SEM) of each test, which is
calculated from the test-retest reliability (r) and the stand-
ard deviation (SD) of test scores: SEM= SD (1-r) 1⁄2. The
standard error (SE) of difference was then calculated as:
SE diff = [2 (SEM
2)] 1⁄2. All Reliable Change Index thresh-
olds were rounded to the nearest whole number. Scores in
any tests decreased from baseline status and met the Reli-
able Change Index threshold were categorized as deterior-
ation at a specific time period (e.g. 3 months, 5 months
and 7 months). The predictive accuracy of various Cox re-
gression models was quantified by Harrell’s concordance
index (C-index), which ranges from 0.5 (no predictive
power) to 1 (perfect prediction). Statistical analyses were
computed using SPSS (version 17.0, SPSS Inc., Chicago,
IL) and the R stats package (R Foundation for Statistical
Computing, Vienna, Austria). Tests were two sided
and p < 0.05 was considered statistically significant.
Results
Patients’ characteristics
From January 2008 to December 2015, 485 NSCLC pa-
tients with BM were retrospectively reviewed. Seventy-
eight patients due to loss of follow-up information, 96
patients due to received EGFR Tyrosine Kinase Inhibitor
(TKIs) and 39 patients due to without WBRT or did not
finish the WBRT were excluded. Nineteen patients had an
operation to treat brain metastases and 15 patients died
within 1 month after starting WBRT were also excluded
(Fig. 1). A total of 238 NSCLC patients with BM were en-
rolled in this study with a median age of 60 years (range,
34–85). There were 129 patients (54.2%) and 109 patients
(45.8%) categorized into RCT arm and RT arm, respect-
ively. Baseline characteristics of patients were well bal-
anced between the matched pairs as shown in Table 1.
Responses and survival of patients
The average intracranial objective response rate (ORR)
and disease control rate (DCR) for all patients were
26.9% (64/238) and 95.8% (228/238), respectively. There
were 164 patients (68.9%) who had intracranial stable
disease and 10 (4.2%) who had intracranial progressive
disease. The intracranial ORR for RCT and RT arm were
34.9% (45/129) vs. 20.2% (22/109) (p = 0.01), respectively.
The intracranial DCR for RCT was 98.4% (127/129)
compared with 92.7% (101/129) for RT arm (p = 0.03).
The median intracranial PFS and OS for all patients were
5.2 months [95% confidence interval (CI), 4.8–5.6 months]
and 7.3 months (95% Cl, 5.9–8.8 months), respectively.
The median intracranial PFS of RCT arm was significantly
longer than that of RT arm (5.9 vs. 4.9 months, p = 0.002)
(Fig. 2). The estimated 3-month PFS rates were 92.1% and
87.9% in the RCT arm and RT arm, respectively. The
median OS of the RCT arm was slightly higher than that of
the RT arm (8.5 vs. 5.9 months) (Fig. 3), but without
statistical significance (p = 0.11). The estimated 6-
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month OS rates were 64.3 and 48.4% in the RCT and
RT arm, respectively.
Table 2 shows the multivariate analysis results on
intracranial PFS and OS for all patients with or without
the Radiation Therapy Oncology Group (RTOG) recur-
sive partitioning analysis (RPA) classification and graded
prognostic assessment (GPA) grade. For multivariate
analysis with RPA and GPA included in the Cox’s regres-
sion model, receiving TMZ (p = 0.004), never smoking
(p = 0.02), primary disease controlled (p = 0.003) and
lower RTOG RPA class (p = 0.008) were of prognostic
significance for intracranial PFS. The C-index of this
model including smoking status, RTOG RPA class,
therapeutic schedule and primary disease situation was
0.726 for intracranial PFS; never smoking (p = 0.03), lower
RTOG RPA class (p = 0.01), RTOG GPA grade 2–4
(p = 0.02) and primary disease controlled (p < 0.001)
were correlated with longer OS. The C-index of the model
was 0.768 for OS. For multivariate analysis without RPA
and GPA entering into Cox’s regression model, TMZ
(p = 0.004), smoking status (p = 0.02), number of BM
(p = 0.02) and primary disease controlled (p = 0.007)
were independent prognostic factors for intracranial
PFS. The C-index of this model including smoking
status, number of BM, therapeutic schedule and pri-
mary disease situation was 0.722 for intracranial PFS;
smoking status (p = 0.03), number of BM (p = 0.02),
performance status (PS) (p = 0.003) and primary dis-
ease controlled (p < 0.001) were associated with OS.
The C-index of the model was 0.758 for OS.
Comparison of NCF and QOL
Table 3 illustrates the compliance to NCF and QOL
assessments at the baseline and over the first 7 months
of follow-up. There was no significant difference on the
compliance between two arms (p > 0.05). Table 4 shows
the deterioration status over 7 months as defined by Re-
liable Change Index threshold baseline. Before treat-
ment, there was no significant difference on the declined
number of scores for NCF and QOL between two
groups (p > 0.05). There were 23 out of 105 evaluated
patients from RCT arm deteriorated in HVLT-R delayed
recall, which were significant lower than (p = 0.02)
those in RT arm, in which 32 out of 87 were deterio-
rated. Statistically significant differences were also
found in TMTB (p = 0.03) and COWA (p = 0.03) at
3 months. For HVLT-R and COWA, there were sig-
nificantly greater deterioration in HVLT-R total recall
(TR) (p = 0.008), HVLT-R delayed recall (p = 0.007),
COWA (p = 0.002), FACT-L (p = 0.01) in the RT arm
compared with RCT arm at 5 months. No statistically
significant differences between the two arms was ob-
served at 7 months (p > 0 .05).
Adverse effects
Side effects comparison between RCT and RT arms were
presented in Table 5. The most frequent hematologic
side effects were anemia (55.9%), neutropenia (52.5%)
and thrombocytopenia (47.1%). The most common
non-hematologic toxicities were nausea (71.8%), fa-
tigue (62.6%), and vomiting (54.6%). The common
grade III/IV toxicity was nausea (20.6%). Neutropenia
and nausea were the two most frequent grade III/IV
hematologic side effects occurred in RCT and RT
arms with a rate of 10.1% vs. 9.2%, and 22.5% vs.
18.3%, respectively. On the whole, all toxicities were
generally brief, reversible, and manageable. They were
well tolerated after symptomatic treatments.
Fig. 1 Flow diagram of patients enrollment
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Discussion
The effects and influence on Neurocognitive function
and QOL of adding TMZ to WBRT in the treatment of
NSCLC with BM were investigated in a total of 238 pa-
tients. Our study suggested that TMZ combined with
WBRT could significantly enhance the intracranial ORR
and DCR, as well as median PFS compared with WBRT
alone in the treatment of NSCLC patients with BM, but
no remarkable difference on median OS was found.
Table 1 Characteristics of NSCLC patients with brain metastasis
Characteristics Total (%) RCT (%) RT (%) P
All patients 238 (100) 129 (100) 109 (100)
Gender
Female 102 (42.9) 60 (46.5) 42 (38.5) 0.22
Male 136 (57.1) 69 (53.5) 67 (61.5)
Smoking
Never 108 (45.4) 63 (48.8) 45 (41.3) 0.24
Current/former 130 (54.6) 66 (51.2) 64 (58.7)
Age
≤60 96 (40.3) 58 (45.0) 38 (35.9) 0.11
>60 142 (59.7) 71 (55.0) 71 (65.1)
Histology
Adenocarcinoma 227 (95.4) 123 (95.3) 104 (95.4) 0.98
Non-adenocarcinoma 11 (4.6) 6 (4.7) 5 (4.6)
ECOG PS
0–1 188 (79.0) 101 (78.3) 87 (79.8) 0.77
2–3 50 (21.0) 28 (21.7) 22 (20.2)
Prior chemotherapy
NO 92 (38.7) 51 (39.5) 41 (37.6) 0.76
YES 146 (61.3) 78 (60.5) 68 (62.4)
Number of BM
≤3 65 (27.3%) 33 (25.6%) 32 (29.4%) 0.52
>3 173 (72.7%) 96 (74.4%) 77 (70.6%)
Extracranial metastases
NO 93 (39.1%) 48 (37.2%) 45 (41.3%) 0.52
YES 145 (60.9%) 81 (62.8%) 64 (58.7%)
Primary disease control
NO 31 (13.0%) 20 (15.5%) 11 (10.1%) 0.22
YES 207 (87.0%) 109 (84.5%) 98 (89.9%)
RTOG RPA class
ClassI 50 (21.0%) 31 (24.0%) 19 (17.4%) 0.21
ClassII + III 188 (79.0%) 98 (76.0%) 90 (82.6%)
RTOG GPA grade
0–2 143 (60.1%) 74 (57.4%) 69 (63.3%) 0.35
2.5–4 95 (39.9%) 55 (42.6%) 40 (36.7%)
Abbreviations: Eastern Cooperative Oncology Group performance status ECOG
PS, Brain metastasis BM, the Radiation Therapy Oncology Group RTOG,
recursive partitioning analysis RPA, graded prognostic assessment GPA
Fig. 2 The intracranial progression-free survival of NSCLC patients
with brain metastases
Fig. 3 The overall survival of NSCLC patients with brain metastases
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NCF and QOL were also prevented from worsening by
adding TMZ.
In this study, the intracranial ORR and DCR of
NSCLC patients with BM treated by WBRT + TMZ
were 34.9 and 98.4%, respectively, which were significantly
higher than 20.2 and 92.7% in the RT arm (both p < 0.05).
These were consistent with results reported in previous
studies that TMZ+WBRT may enhance the overall ORR
of NSCLC patients with BM compared with WBRT alone
[23, 24]. A multi-institutional trial showed a higher overall
Table 2 Multivariate analysis of factors affecting intracranial PFS and OS in NSCLC patients with brain metastasis
Factors Intracranial PFS OS
N HR 95%CI P HR 95%CI P
With RPA and GPA in the model
Smoking 108/130 1.42 1.07–1.88 0.02 1.48 1.04–2.10 0.03
Primary disease controlled 31/207 0.54 0.36–0.81 0.003 0.36 0.23–0.57 <0.001
RTOG RPA class 50/188 1.81 1.17–2.79 0.008 1.99 1.15–3.45 0.01
Therapeutic schedule 109/129 0.66 0.50–0.88 0.004
RTOG GPA grade 143/95 0.58 0.36–0.93 0.02
Without RPA and GPA in the model
Smoking 108/130 1.39 1.04–1.84 0.02 1.48 1.05–2.10 0.03
Number of BM 65/173 1.47 1.08–2.00 0.02 1.58 1.08–2.33 0.02
Primary disease controlled 31/207 0.57 0.38–0.86 0.007 0.38 0.24–0.60 <0.001
Therapeutic schedule 109/129 0.66 0.50–0.88 0.004
EGOC PS 188/50 1.76 1.21–2.57 0.003
Abbreviations: RPA recursive partitioning analysis, GPA graded prognostic assessment, BM brain metastasis, Eastern Cooperative Oncology Group performance
status ECOG PS, the Radiation Therapy Oncology Group RTOG, confidence interval CI, hazard ratio HR
Table 3 Neurocognitive and quality of life assessment compliance
Evaluation
Status
RCT arm RT arm P
Not evaluated Received Not evaluated Received
Hopkins Verbal Learning Test (HVLT-R)
Baseline 5 124 4 105 0.93
At 3 Months 24 105 32 87 0.12
At 5 Months 57 72 55 64 0.75
At 7 Months 87 42 83 36 0.70
Trail-making Test (TMT)
Baseline 6 123 4 105 0.71
At 3 Months 26 103 31 88 0.27
At 5 Months 59 70 57 62 0.73
At 7 Months 85 44 83 36 0.52
Controlled Oral Word Association (COWA) test
Baseline 5 124 6 103 0.55
At 3 Months 24 105 30 89 0.21
At 5 Months 57 72 58 61 0.47
At 7 Months 85 44 85 34 0.35
Functional Assessment of Cancer Treatment-Lung (FACT-L)
Baseline 7 122 9 100 0.48
At 3 Months 27 102 34 85 0.16
At 5 Months 56 73 54 65 0.76
At 7 Months 88 41 86 33 0.49
Abbreviations: Hopkins Verbal Learning Test HVLT-R, Trail-making Test TMT, Controlled Oral Word Association test COWA, Functional Assessment of Cancer
Treatment-Lung FACT-L
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ORR (48% vs. 27%, p = 0.03) in 103 lung cancer pa-
tients with BM treated with TMZ 75 mg/m2 per day
plus WBRT compared with WBRT alone [24]. Through a
meta-analysis, Liao Kai et al. also reported that WBRT +
TMZ could significantly improve ORR (risk ratio =
1.55, p = 0.003) in the treatment of BM from NSCLC
compared with WBRT alone [23]. However, a phase II
trial reported that adding TMZ to WBRT did not im-
prove the ORR compared with WBRT alone for 12
chemotherapy-native NSCLC patients with BM [25]. In
another phase II trial, for 30 pre-treated recurrent NSCLC
patients with BM treated by concurrent WBRT and TMZ
(150–200 mg/m2/d), only 3 (10) and 6 (20%) patients
achieved an objective response and disease control [26].
We inferred that pretreatment influenced the efficacy of
TMZ in these phase II patients.
The median OS for all NSCLC patients with BM ob-
served in this study was 7.3 months, which is close to
Table 4 Deterioration status from baseline in each examination using reliable change index
Deterioration
status
RCT arm RT arm p
Deterioration No deterioration Deterioration No deterioration
At 3 months
HVLT-R TR 21 84 19 68 0.76
HVLT-R DR 23 82 32 55 0.02
TMT Part A 22 81 25 63 0.26
TMT Part B 24 79 33 55 0.03
COWA 19 86 28 61 0.03
FACT-L 23 79 24 61 0.45
At 5 months
HVLT-R TR 21 511 33 31 0.008
HVLT-R DR 23 49 35 29 0.007
TMT Part A 18 52 25 37 0.07
TMT Part B 21 49 30 32 0.03
COWA 19 53 32 29 0.002
FACT-L 25 48 36 29 0.01
At 7 months
HVLT-R TR 20 22 19 17 0.65
HVLT-R DR 24 18 17 19 0.38
TMT Part A 23 21 21 15 0.59
TMT Part B 25 19 22 14 0.70
COWA 24 20 20 14 0.71
FACT-L 24 17 21 12 0.66
Abbreviations: HVLT-R TR Hopkins Verbal Learning Test total recall, HVLT-R DR Hopkins Verbal Learning Test delayed recall, TMT Trail-making Test, COWA Controlled
Oral Word Association, FACT-L Functional Assessment of Cancer Treatment-Lung
Table 5 Toxicity profile for the NSCLC with brain metastasis patients treated by CRT and RT
Side effects/N (%) RCT arm (N = 129) RT arm (N = 109) P for all
grades
P for grade
III/IVAll grades Grade III/IV All grades Grade III/IV
Fatigue 81 (62.8) 16 (12.4) 68 (62.4) 12 (11.0) 0.95 0.74
Anorexia 64 (49.6) 14 (10.9) 47 (43.1) 9 (8.3) 0.29 0.50
Diarrhea 18 (13.9) 0 (0%) 12 (11.0) 0 (0%) 0.50 NA
Nausea 88 (68.2) 29 (22.5) 83 (76.1) 20 (18.3) 0.18 0.43
Vomiting 69 (53.5) 14 (10.9) 61 (56.0) 13 (11.9) 0.70 0.80
Headache 55 (42.6) 13 (10.1) 43 (39.4) 11 (10.1) 0.62 0.99
Anemia 72 (55.8) 5 (3.9) 61 (56.0) 3 (2.8) 0.98 0.91
Neutropenia 66 (51.2) 13 (10.1) 59 (54.1) 10 (9.2) 0.65 0.81
Thrombocytopenia 61 (47.3) 4 (3.1) 51 (46.8) 2 (1.8) 0.94 0.84
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the reported median OS of 8.0 months in the study of
Wang Q et al., in which NSCLC patients with BM were
treated by WBRT followed by intensity-modulated boost
combined with concomitant TMZ [16]. In this study, the
median OS and PFS in the WBRT + TMZ group and in
the WBRT alone group were 8.5 vs. 5.9 months and 5.9
vs. 4.9 months, respectively. Daniel Chua et al. also
demonstrated that WBRT + TMZ had a higher median
OS (5.7 vs. 4.4 months) and PFS (3.8 vs. 3.1 months)
compared with WBRT alone in the treatment of NSCLC
patients with BM [27]. However, their reported median
OS and PFS were inferior than ours. We speculated that
the difference may resulted from different TMZ doses
were administered in two studies. In the study of Daniel
Chua, patients received TMZ daily for 21 days, while in
our study, TMZ 75 mg/m2/day was administered daily
during radiation treatment and TMZ 100 mg/m2/day
was continued for 14 days and repeated every 28 days
until unacceptable toxicity or disease progression for up
to six cycles.
Previous studies reported that TMZ combing with RT
could improve QOL in high grade glioma [28, 29]. A
single-institution phase I clinical trial on patients with
multiple brain lesions from breast carcinoma treated by
capecitabine and TMZ demonstrated that significant im-
provements in attention span (p = 0.047) and emotional
function (p = 0.016) were observed indicating that
adding TMZ was not neurotoxic and may have a benefi-
cial effect [30]. Addeo R et al. also reported that a statis-
tically significant improvement on QOL was found at
3,6 and 9 months for 59 patients treated by 30 Gy
WBRT with concomitant TMZ [31]. Similarly, our result
implied that adding TMZ in the treatment of NSCLC
patients with BM could prevent the NCF and QOL from
worsening at 5 months. These studies implied that TMZ
as a maintenance therapy may improve patients’ NCF
and QOL. This may due to a better intracranial ORR
and DCR in RCT group. TMZ may has a certain func-
tion of preventing tumor recurrence in brain.
Nausea and fatigue were the most frequent side effects
observed for both RCT and RT arms, followed by anemia,
vomiting, neutropenia, anorexia and thrombocytopenia,
etc. Addition TMZ in the RCT arm showed a trend of
increasing the rate of side effects compared with RT alone,
as reported in previous studies [27, 32]. However, the
difference of the adverse events occurrence between RCT
and RT arms was not statistically significant.
One limitation of current study is that it is a retrospect-
ive methodology from a single institution experience. The
impact of various treatments related outcomes could not
be fully evaluated. The number of patients enrolled may
not be sufficient enough and the follow-up duration of the
study may not be long enough. External validation using
other large database for further evaluating the prognostic
effect of adding TMZ in the treatment of NSCLC patients
with BM would be of great value in clinical practice.
Conclusion
In a conclusion, adding TMZ to WBRT in the treatment
of NSCLC patients with BM could improve the intracra-
nial ORR and DCR, as well as median PFS compared with
WBRT alone. However, no remarkable difference on me-
dian OS was found. NCF and QOL were also prevented
from worsening by adding TMZ. Although the side effects
were increased by adding TMZ, the difference was not
statistical significance and they were well tolerated.
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oncology group; TKIs: Tyrosine kinase inhibitor; TMT: Trail-making test;
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